July 14, 2020
SymBio Pharmaceuticals said on July 13 that it has filed its cancer drug Treakisym (bendamustine) in Japan for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in combination with polatuzumab vedotin and Rituxan (rituximab). Chugai Pharmaceutical has...read more